STING agonists are estimated at 46.0% by drug type in 2026, with oncology projected at 48.0% and monotherapy at 42.0%. Adoption depends on tissue-selective pathway control as systemic inflammation and uneven response durability restrict wider clinical use.
Cgas Sting Pathway Market Analysis By ApplicationCgas Sting Pathway Market Analysis By Distribution ChannelCgas Sting Pathway Market Analysis By End UserCgas Sting Pathway Market Analysis By Therapy ModalityCgas Sting Pathway Market Opportunity Matrix Growth Vs ValueCgas Sting Pathway Market Breakdown By Drug Type, Application, And Region